Tom Powles, Professor at the University of London, shared a post on X:
“Bladder cancer ASCO 2025
1) Ipi/nivo vs 1st line chemo (HR 0.79)-near miss
2) maintenance SG/PD-L1 vs PD-L1 (PFS HR0.49)-still relevant?
3) CIS subset analysis for salanlimab in NMIBC-patent selection for therapy?
4) A new Nectin4 ADC 9MW/PD1 in phase II RR=88%!
5) EVP update on RR/tox.”
More posts featuring ASCO 2025.